CompletedNot Applicable

Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)

Italy13 participantsStarted 2021-06-30

Plain-language summary

Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that produces spatacsin, a protein involved in lysosomal function.

Who can participate

Age range10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of SPG11 * Written signed informed consent Exclusion Criteria: * Diagnosis of other concomitant neurodegenerative diseases * taking other experimental drugs within 30 days of the first Study visit (T0) and during the study * Refusal to sign informed consent

What they're measuring

Changes from baseline in Spastic Paraplegia Rating Scale (SPRS) at 6 and 12 months

Timeframe: At baseline, month 6, month 12

Trial details

NCT IDNCT04912609

SponsorIRCCS Fondazione Stella Maris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-30

View on ClinicalTrials.gov More Hereditary Spastic Paraplegia trials